Neuberger Berman Group
VYGR icon

Neuberger Berman Group’s Voyager Therapeutics VYGR Stock Holding History

Neuberger Berman Group’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-20,696
Closed -$392K – 1661
2018
Q3 		$392K Hold
20,696
– – ﹤0.01% 1363
2018
Q2 		$404K Buy
20,696
+456
+2% +$9.01K ﹤0.01% 1435
2018
Q1 		$380K Buy
20,240
+9,350
+86% +$202K ﹤0.01% 1413
2017
Q4 		$181K Buy
+10,890
New +$187K ﹤0.01% 1702

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Neuberger Berman Group's VYGR Position: Q4 2018 in Review

Neuberger Berman Group sold out of Voyager Therapeutics (VYGR) in Q4 2018, closing a stake of 20,696 shares — an estimated $392K sold.

Neuberger Berman Group first reported a position in VYGR in Q4 2017 and held it in 4 quarters. The position peaked at $404K in Q2 2018. 116 funds tracked by Wall St. Rank hold VYGR as of Q4 2018.

  • Neuberger Berman Group reported no remaining Voyager Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Neuberger Berman Group sold 20,696 Voyager Therapeutics shares in Q4 2018, an estimated $392K.
  • Neuberger Berman Group first reported a position in Voyager Therapeutics in Q4 2017 and held it in 4 quarters.
  • Neuberger Berman Group's Voyager Therapeutics position peaked at $404K in Q2 2018.
  • 116 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2018.

Based on Neuberger Berman Group's 13F filing for Q4 2018, filed 12 Feb 2019.